Pluripotent stem cells for gene therapy of degenerative muscle diseases

Current Gene Therapy

Volumn 15, Issue 4, 2015, Pages 364-380

  Loperfido, Mariana ^a,b   Steele Stallard, Heather B ^c   Tedesco, Francesco Saverio ^c   VandenDriessche, Thierry ^a,b  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Cell therapy; Designer nucleases; Embryonic stem cells; Gene therapy; Induced pluripotent stem (iPS) cells; Muscle stem cells; Muscular dystrophies; Regenerative medicine

Indexed keywords

CRISPR ASSOCIATED PROTEIN; KRUPPEL LIKE FACTOR 4; MYOD1 PROTEIN; MYOGENIC FACTOR 5; MYOGENIC FACTOR 6; OCTAMER TRANSCRIPTION FACTOR 4; TRANSCRIPTION ACTIVATOR LIKE EFFECTOR NUCLEASE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR PAX3; TRANSCRIPTION FACTOR PAX7; TRANSCRIPTION FACTOR SOX; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; ZINC FINGER NUCLEASE; MYOD PROTEIN; PAIRED BOX TRANSCRIPTION FACTOR; PAX3 PROTEIN, MOUSE; PAX7 PROTEIN, MOUSE;

ADULT STEM CELL; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CELL DIFFERENTIATION; DNA MODIFICATION; DUCHENNE MUSCULAR DYSTROPHY; EMBRYONIC STEM CELL; FLUORESCENCE ACTIVATED CELL SORTING; GENE INSERTION; GENETIC DISORDER; HUMAN; LIMB GIRDLE MUSCULAR DYSTROPHY; MUSCLE REGENERATION; MUSCLE STEM CELL; MUSCULAR DYSTROPHY; NONHUMAN; PLURIPOTENT STEM CELL; PROTEIN EXPRESSION; REGENERATIVE MEDICINE; SKELETAL MUSCLE; STEM CELL GENE THERAPY; ANIMAL; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEAT; CYTOLOGY; GENE THERAPY; GENETICS; GROWTH, DEVELOPMENT AND AGING; INDUCED PLURIPOTENT STEM CELL; MOUSE; MUSCULAR DISEASES; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; REGENERATION; STEM CELL TRANSPLANTATION; TRANSPLANTATION;

IPS;

ADULT STEM CELLS; ANIMALS; CELL DIFFERENTIATION; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEATS; GENETIC THERAPY; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MICE; MUSCLE, SKELETAL; MUSCULAR DISEASES; MYOD PROTEIN; PAIRED BOX TRANSCRIPTION FACTORS; PAX7 TRANSCRIPTION FACTOR; PLURIPOTENT STEM CELLS; REGENERATION; STEM CELL TRANSPLANTATION;

EID: 84938697138     PISSN: 15665232     EISSN: 18755631     Source Type: Journal    
DOI: 10.2174/1566523215666150630121207     Document Type: Article

References (164)

1. Mauro A. Satellite cell of skeletal muscle fibers. J Biophys Biochem Cytol 1961; 9: 493-5.
2. Benedetti S, Hoshiya H, Tedesco FS. Repair or replace? Exploiting novel gene and cell therapy strategies for muscular dystrophies. FEBS J 2013; 280: 4263-80. doi: 10.1111/febs.12178.
3. Blau HM, Webster C, Pavlath GK. Defective myoblasts identified in Duchenne muscular dystrophy. Proc Natl Acad Sci U S A 1983; 80: 4856-60.
4. Cassano M, Dellavalle A, Tedesco FS, et al. Alpha sarcoglycan is required for FGF-dependent myogenic progenitor cell proliferation in vitro and in vivo. Development 2011; 138: 4523-33. doi: 10.1242/dev.070706.
5. Cohn RD, Henry MD, Michele DE, Barresi R, Saito F, Moore SA, et al. Disruption of DAG1 in differentiated skeletal muscle reveals a role for dystroglycan in muscle regeneration. Cell 2002; 110: 639-48.
6. Kudryashova E, Kramerova I, Spencer MJ. Satellite cell senescence underlies myopathy in a mouse model of limb-girdle muscular dystrophy 2H. J Clin Invest 2012; 122: 1764-76. doi: 10.1172/JCI59581.
7. Montarras D, Morgan J, Collins C, Relaix F, Zaffran S, Cumano A, et al. Direct isolation of satellite cells for skeletal muscle regeneration. Science 2005; 309: 2064-7. doi: 10.1126/science.1114758.
8. Sacco A, Mourkioti F, Tran R, Choi J, Llewellyn M, Kraft P, et al. Short telomeres and stem cell exhaustion model Duchenne muscular dystrophy in mdx/mTR mice. Cell 2010; 143: 1059-71. doi: 10.1016/j.cell.2010.11.039.
9. Tedesco FS, Gerli MFM, Perani L, Benedetti S, Ungaro F, Cassano M, et al. Transplantation of genetically corrected human iPSCderived progenitors in mice with limb-girdle muscular dystrophy. Sci Transl Med 2012; 4: 140ra89. doi: 10.1126/scitranslmed.3003541.
10. Evans MJ, Kaufman MH. Establishment in culture of pluripotential cells from mouse embryos. Nature 1981; 292: 154-6.
11. Thomson JA, Itskovitz-Eldor J, Shapiro SS, et al. Embryonic stem cell lines derived from human blastocysts. Science 1998; 282: 1145-7.
12. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006; 126: 663-76. doi: 10.1016/j.cell.2006.07.024.
13. Takahashi K, Tanabe K, Ohnuki M, Narita M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007; 131: 861-72. doi: 10.1016/j.cell.2007.11.019.
14. Janssen I, Heymsfield SB, Wang ZM, Ross R. Skeletal muscle mass and distribution in 468 men and women aged 18-88 yr. J Appl Physiol 1985 2000; 89: 81-8.
15. Tajbakhsh S. Skeletal muscle stem cells in developmental versus regenerative myogenesis. J Intern Med 2009; 266: 372-89. doi: 10.1111/j.1365-2796.2009.02158.x.
16. Cossu G, Tajbakhsh S, Buckingham M. How is myogenesis initiated in the embryo? Trends Genet 1996; 12: 218-23.
17. Miller JB, Schaefer L, Dominov JA. Seeking muscle stem cells. Curr Top Dev Biol 1999; 43: 191-219.
18. Pirskanen A, Kiefer JC, Hauschka SD. IGFs, insulin, Shh, bFGF, and TGF-beta1 interact synergistically to promote somite myogenesis in vitro. Dev Biol 2000; 224: 189-203. doi: 10.1006/dbio.2000.9784.
19. Buckingham M, Bajard L, Chang T, Daubas P, et al. The formation of skeletal muscle: from somite to limb. J Anat 2003; 202: 59-68.
20. Tajbakhsh S, Buckingham M. The birth of muscle progenitor cells in the mouse: spatiotemporal considerations. Curr Top Dev Biol 2000; 48: 225-68.
21. Borycki AG, Emerson CP. Multiple tissue interactions and signal transduction pathways control somite myogenesis. Curr Top Dev Biol 2000; 48: 165-224.
22. Bryson-Richardson RJ, Currie PD. The genetics of vertebrate myogenesis. Nat Rev Genet 2008; 9: 632-46. doi: 10.1038/nrg2369.
23. Tzahor E. Heart and craniofacial muscle development: a new developmental theme of distinct myogenic fields. Dev Biol 2009; 327: 273-9. doi: 10.1016/j.ydbio.2008.12.035.
24. Harel I, Nathan E, Tirosh-Finkel L, Zigdon H, et al. Distinct origins and genetic programs of head muscle satellite cells. Dev Cell 2009; 16: 822-32. doi: 10.1016/j.devcel.2009.05.007.
25. Emery AEH. The muscular dystrophies. Lancet 2002; 359: 687-95. doi: 10.1016/S0140-6736(02)07815-7.
26. Rudnicki MA, Schnegelsberg PN, Stead RH, Braun T, Arnold HH, Jaenisch R. MyoD or Myf-5 is required for the formation of skeletal muscle. Cell 1993; 75: 1351-9.
27. Kassar-Duchossoy L, Gayraud-Morel B, Gomès D, et al. Mrf4 determines skeletal muscle identity in Myf5: Myod double-mutant mice. Nature 2004; 431: 466-71. doi: 10.1038/nature02876.
28. Kassar-Duchossoy L, Giacone E, Gayraud-Morel B, Jory A, Gomès D, Tajbakhsh S. Pax3/Pax7 mark a novel population of primitive myogenic cells during development. Genes Dev 2005; 19: 1426-31. doi: 10.1101/gad.345505.
29. Relaix F, Rocancourt D, Mansouri A, Buckingham M. A Pax3/Pax7-dependent population of skeletal muscle progenitor cells. Nature 2005; 435: 948-53. doi: 10.1038/nature03594.
30. Gros J, Manceau M, Thomé V, Marcelle C. A common somitic origin for embryonic muscle progenitors and satellite cells. Nature 2005; 435: 954-8. doi: 10.1038/nature03572.
31. Schienda J, Engleka KA, Jun S, Hansen MS, Epstein JA, Tabin CJ, et al. Somitic origin of limb muscle satellite and side population cells. Proc Natl Acad Sci U S A 2006; 103: 945-50. doi: 10.1073/pnas.0510164103.
32. Mikkers H, Frisén J. Deconstructing stemness. EMBO J 2005; 24: 2715-9. doi: 10.1038/sj.emboj.7600749.
33. Relaix F, Montarras D, Zaffran S, Gayraud-Morel B, et al. Pax3 and Pax7 have distinct and overlapping functions in adult muscle progenitor cells. J Cell Biol 2006; 172: 91-102. doi: 10.1083/jcb.200508044.
34. Valdez MR, Richardson JA, Klein WH, Olson EN. Failure of Myf5 to support myogenic differentiation without myogenin, MyoD, and MRF4. Dev Biol 2000; 219: 287-98. doi: 10.1006/dbio.2000.9621.
35. Maroto M, Reshef R, Münsterberg AE, Koester S, et al. Ectopic Pax-3 activates MyoD and Myf-5 expression in embryonic mesoderm and neural tissue. Cell 1997; 89: 139-48.
36. Tajbakhsh S, Rocancourt D, Cossu G, et al. Redefining the genetic hierarchies controlling skeletal myogenesis: Pax-3 and Myf-5 act upstream of MyoD. Cell 1997; 89: 127-38.
37. Mercuri E, Muntoni F. Muscular dystrophies. Lancet 2013; 381: 845-60. doi: 10.1016/S0140-6736(12)61897-2.
38. Lepper C, Partridge TA, Fan C-M. An absolute requirement for Pax7-positive satellite cells in acute injury-induced skeletal muscle regeneration. Development 2011; 138: 3639-46. doi: 10.1242/dev.067595.
39. Murphy MM, Lawson JA, Mathew SJ, et al. Satellite cells, connective tissue fibroblasts and their interactions are crucial for muscle regeneration. Development 2011; 138: 3625-37. doi: 10.1242/dev.064162.
40. Relaix F, Zammit PS. Satellite cells are essential for skeletal muscle regeneration: the cell on the edge returns centre stage. Development 2012; 139: 2845-56. doi: 10.1242/dev.069088.
41. Sambasivan R, Yao R, Kissenpfennig A, Van Wittenberghe L, et al. Pax7-expressing satellite cells are indispensable for adult skele tal muscle regeneration. Development 2011; 138: 3647-56. doi: 10.1242/dev.067587.
42. Günther S, Kim J, Kostin S, Lepper C, et al. Myf5-positive satellite cells contribute to Pax7-dependent long-term maintenance of adult muscle stem cells. Cell Stem Cell 2013; 13: 590-601. doi: 10.1016/j.stem.2013.07.016.
43. Schultz E, Gibson MC, Champion T. Satellite cells are mitotically quiescent in mature mouse muscle: an EM and radioautographic study. J Exp Zool 1978; 206: 451-6. doi: 10.1002/jez.1402060314.
44. Tedesco FS, Dellavalle A, Diaz-Manera J, et al. Repairing skeletal muscle: regenerative potential of skeletal muscle stem cells. J Clin Invest 2010; 120: 11-9. doi: 10.1172/JCI40373.
45. Seale P, Sabourin LA, Girgis-Gabardo A, Mansouri A, et al. Pax7 is required for the specification of myogenic satellite cells. Cell 2000; 102: 777-86.
46. Zammit PS, Relaix F, Nagata Y, Ruiz AP, et al. Pax7 and myogenic progression in skeletal muscle satellite cells. J Cell Sci 2006; 119: 1824-32. doi: 10.1242/jcs.02908.
47. Sherwood RI, Christensen JL, Conboy IM, Conboy MJ, et al. Isolation of adult mouse myogenic progenitors: functional heterogeneity of cells within and engrafting skeletal muscle. Cell 2004; 119: 543-54. doi: 10.1016/j.cell.2004.10.021.
48. Bajard L, Relaix F, Lagha M, Rocancourt D, et al. A novel genetic hierarchy functions during hypaxial myogenesis: Pax3 directly activates Myf5 in muscle progenitor cells in the limb. Genes Dev 2006; 20: 2450-64. doi: 10.1101/gad.382806.
49. Hu P, Geles KG, Paik J-H, DePinho RA, Tjian R. Codependent activators direct myoblast-specific MyoD transcription. Dev Cell 2008; 15: 534-46. doi: 10.1016/j.devcel.2008.08.018.
50. McKinnell IW, Ishibashi J, Le Grand F, et al. Pax7 activates myogenic genes by recruitment of a histone methyltransferase complex. Nat Cell Biol 2008; 10: 77-84. doi: 10.1038/ncb1671.
51. Bober E, Franz T, Arnold HH, Gruss P, Tremblay P. Pax-3 is required for the development of limb muscles: a possible role for the migration of dermomyotomal muscle progenitor cells. Development 1994; 120: 603-12.
52. Relaix F, Rocancourt D, Mansouri A, et al. Divergent functions of murine Pax3 and Pax7 in limb muscle development. Genes Dev 2004; 18: 1088-105. doi: 10.1101/gad.301004.
53. Lepper C, Conway SJ, Fan C-M. Adult satellite cells and embryonic muscle progenitors have distinct genetic requirements. Nature 2009; 460: 627-31. doi: 10.1038/nature08209.
54. Von Maltzahn J, Jones AE, Parks RJ, Rudnicki MA. Pax7 is critical for the normal function of satellite cells in adult skeletal muscle. Proc Natl Acad Sci U S A 2013; 110: 16474-9. doi: 10.1073/pnas.1307680110.
55. Punch VG, Jones AE, Rudnicki MA. Transcriptional networks that regulate muscle stem cell function. Wiley Interdiscip Rev Syst Biol Med 2009; 1: 128-40. doi: 10.1002/wsbm.11.
56. Le Grand F, Jones AE, Seale V, et al. Wnt7a activates the planar cell polarity pathway to drive the symmetric expansion of satellite stem cells. Cell Stem Cell 2009; 4: 535-47. doi: 10.1016/j.stem.2009.03.013.
57. Kuang S, Gillespie MA, Rudnicki MA. Niche regulation of muscle satellite cell self-renewal and differentiation. Cell Stem Cell 2008; 2: 22-31. doi: 10.1016/j.stem.2007.12.012.
58. Rocheteau P, Gayraud-Morel B, Siegl-Cachedenier I, Blasco MA, Tajbakhsh S. A subpopulation of adult skeletal muscle stem cells retains all template DNA strands after cell division. Cell 2012; 148: 112-25. doi: 10.1016/j.cell.2011.11.049.
59. Shinin V, Gayraud-Morel B, Gomès D, et al. Asymmetric division and cosegregation of template DNA strands in adult muscle satellite cells. Nat Cell Biol 2006; 8: 677-87. doi: 10.1038/ncb1425.
60. Wang YX, Bentzinger CF, Rudnicki MA. Molecular regulation of determination in asymmetrically dividing muscle stem cells. Cell Cycle 2013; 12: 3-4. doi: 10.4161/cc.23068.
61. Zammit PS, Golding JP, Nagata Y, Hudon V, et al. Muscle satellite cells adopt divergent fates: a mechanism for self-renewal? J Cell Biol 2004; 166: 347-57. doi: 10.1083/jcb.200312007.
62. Péault B, Rudnicki M, Torrente Y, Cossu G, et al. Stem and progenitor cells in skeletal muscle development, maintenance, and therapy. Mol Ther 2007; 15: 867-77. doi: 10.1038/mt.sj.6300145.
63. Illa I, Leon-Monzon M, Dalakas MC. Regenerating and denervated human muscle fibers and satellite cells express neural cell adhesion molecule recognized by monoclonal antibodies to natural killer cells. Ann Neurol 1992; 31: 46-52. doi: 10.1002/ana.410310109.
64. Partridge TA, Morgan JE, Coulton GR, et al. Conversion of mdx myofibres from dystrophin-negative to -positive by injection of normal myoblasts. Nature 1989; 337: 176-9. doi: 10.1038/337176a0.
65. Skuk D, Tremblay JP. Clarifying misconceptions about myoblast transplantation in myology. Mol Ther 2014; 22: 897-8. doi: 10.1038/mt.2014.57.
66. Périé S, Mamchaoui K, Mouly V, Blot S, et al. Premature proliferative arrest of cricopharyngeal myoblasts in oculo-pharyngeal muscular dystrophy: Therapeutic perspectives of autologous myoblast transplantation. Neuromuscul Disord 2006; 16: 770-81. doi: 10.1016/j.nmd.2006.07.022.
67. Périé S, Trollet C, Mouly V, Vanneaux V, et al. Autologous myoblast transplantation for oculopharyngeal muscular dystrophy: a phase I/IIa clinical study. Mol Ther 2014; 22: 219-25. doi: 10.1038/mt.2013.155.
68. Benchaouir R, Meregalli M, Farini A, D'Antona G, et al. Restoration of human dystrophin following transplantation of exonskipping- engineered DMD patient stem cells into dystrophic mice. Cell Stem Cell 2007; 1: 646-57. doi: 10.1016/j.stem.2007.09.016.
69. Torrente Y, Belicchi M, Marchesi C, D'Antona G, et al. Autologous transplantation of muscle-derived CD133+ stem cells in Duchenne muscle patients. Cell Transplant 2007; 16: 563-77.
70. Meng J, Chun S, Asfahani R, Lochmüller H, et al. Human skeletal muscle-derived CD133(+) cells form functional satellite cells after intramuscular transplantation in immunodeficient host mice. Mol Ther 2014; 22: 1008-17. doi: 10.1038/mt.2014.26.
71. Mitchell KJ, Pannérec A, Cadot B, Parlakian A, et al. Identification and characterization of a non-satellite cell muscle resident progenitor during postnatal development. Nat Cell Biol 2010; 12: 257- 66. doi: 10.1038/ncb2025.
72. Rouger K, Larcher T, Dubreil L, Deschamps J-Y, et al. Systemic delivery of allogenic muscle stem cells induces long-term muscle repair and clinical efficacy in duchenne muscular dystrophy dogs. Am J Pathol 2011; 179: 2501-18. doi: 10.1016/j.ajpath.2011.07.022.
73. Dellavalle A, Maroli G, Covarello D, Azzoni E, et al. Pericytes resident in postnatal skeletal muscle differentiate into muscle fibres and generate satellite cells. Nat Commun 2011; 2: 499. doi: 10.1038/ncomms1508.
74. Minasi MG, Riminucci M, De Angelis L, Borello U, et al. The meso-angioblast: a multipotent, self-renewing cell that originates from the dorsal aorta and differentiates into most mesodermal tissues. Development 2002; 129: 2773-83.
75. Cappellari O, Cossu G. Pericytes in development and pathology of skeletal muscle. Circ Res 2013; 113: 341-7. doi: 10.1161/CIRCRESAHA.113.300203.
76. Sampaolesi M, Torrente Y, Innocenzi A, et al. Cell therapy of alpha-sarcoglycan null dystrophic mice through intra-arterial delivery of mesoangioblasts. Science 2003; 301: 487-92. doi: 10.1126/science.1082254.
77. Sampaolesi M, Blot S, D'Antona G, Granger N, et al. Mesoangioblast stem cells ameliorate muscle function in dystrophic dogs. Nature 2006; 444: 574-9. doi: 10.1038/nature05282.
78. Gargioli C, Coletta M, De Grandis F, et al. PlGF-MMP-9- expressing cells restore microcirculation and efficacy of cell therapy in aged dystrophic muscle. Nat Med 2008; 14: 973-8. doi: 10.1038/nm.1852.
79. Díaz-Manera J, Touvier T, Dellavalle A, Tonlorenzi R, et al. Partial dysferlin reconstitution by adult murine mesoangioblasts is sufficient for full functional recovery in a murine model of dysferlinopathy. Cell Death Dis 2010; 1: e61. doi: 10.1038/cddis.2010.35.
80. Tedesco FS, Hoshiya H, D'Antona G, Gerli MFM, et al. Stem cellmediated transfer of a human artificial chromosome ameliorates muscular dystrophy. Sci Transl Med 2011; 3: 96ra78. doi: 10.1126/scitranslmed.3002342.
81. Giannotta M, Benedetti S, Tedesco FS, Corada M, et al. Targeting endothelial junctional adhesion molecule-A/ EPAC/ Rap-1 axis as a novel strategy to increase stem cell engraftment in dystrophic muscles. EMBO Mol Med 2014; 6: 239-58. doi: 10.1002/emmm.201302520.
82. Martin GR. Isolation of a pluripotent cell line from early mouse embryos cultured in medium conditioned by teratocarcinoma stem cells. Proc Natl Acad Sci U S A 1981; 78: 7634-8.
83. Robbins J, Gulick J, Sanchez A, et al. Mouse embryonic stem cells express the cardiac myosin heavy chain genes during development in vitro. J Biol Chem 1990; 265: 11905-9.
84. Sánchez A, Jones WK, Gulick J, et al. Myosin heavy chain gene expression in mouse embryoid bodies. An in vitro developmental study. J Biol Chem 1991; 266: 22419-26.
85. Bhagavati S, Xu W. Generation of skeletal muscle from transplanted embryonic stem cells in dystrophic mice. Biochem Biophys Res Commun 2005; 333: 644-9. doi: 10.1016/j.bbrc.2005.05.135.
86. Barberi T, Bradbury M, Dincer Z, et al. Derivation of engraftable skeletal myoblasts from human embryonic stem cells. Nat Med 2007; 13: 642-8. doi: 10.1038/nm1533.
87. Lassar AB, Paterson BM, Weintraub H. Transfection of a DNA locus that mediates the conversion of 10T1/2 fibroblasts to myoblasts. Cell 1986; 47: 649-56.
88. Dekel I, Magal Y, Pearson-White S, et al. Conditional conversion of ES cells to skeletal muscle by an exogenous MyoD1 gene. New Biol 1992; 4: 217-24.
89. Shani M, Faerman A, Emerson CP, Pearson-White S, et al. The consequences of a constitutive expression of MyoD1 in ES cells and mouse embryos. Symp Soc Exp Biol 1992; 46: 19-36.
90. Ozasa S, Kimura S, Ito K, Ueno H, et al. Efficient conversion of ES cells into myogenic lineage using the gene-inducible system. Biochem Biophys Res Commun 2007; 357: 957-63. doi: 10.1016/j.bbrc.2007.04.032.
91. Darabi R, Gehlbach K, Bachoo RM, Kamath S, et al. Functional skeletal muscle regeneration from differentiating embryonic stem cells. Nat Med 2008; 14: 134-43. doi: 10.1038/nm1705.
92. Darabi R, Santos FNC, Filareto A, Pan W, et al. Assessment of the myogenic stem cell compartment following transplantation of Pax3/Pax7-induced embryonic stem cell-derived progenitors. Stem Cells 2011; 29: 777-90. doi: 10.1002/stem.625.
93. Darabi R, Arpke RW, Irion S, Dimos JT, et al. Human ES- and iPS-derived myogenic progenitors restore DYSTROPHIN and improve contractility upon transplantation in dystrophic mice. Cell Stem Cell 2012; 10: 610-9. doi: 10.1016/j.stem.2012.02.015.
94. Iacovino M, Bosnakovski D, Fey H, Rux D, et al. Inducible cassette exchange: a rapid and efficient system enabling conditional gene expression in embryonic stem and primary cells. Stem Cells 2011; 29: 1580-8.
95. Sakurai H, Okawa Y, Inami Y, et al. Paraxial mesodermal progenitors derived from mouse embryonic stem cells contribute to muscle regeneration via differentiation into muscle satellite cells. Stem Cells 2008; 26: 1865-73. doi: 10.1634/stemcells.2008-0173.
96. Chang H, Yoshimoto M, Umeda K, Iwasa T, et al. Generation of transplantable, functional satellite-like cells from mouse embryonic stem cells. FASEB J 2009; 23: 1907-19. doi: 10.1096/fj.08- 123661.
97. Fukada S, Higuchi S, Segawa M, Koda K, et al. Purification and cell-surface marker characterization of quiescent satellite cells from murine skeletal muscle by a novel monoclonal antibody. Exp Cell Res 2004; 296: 245-55. doi: 10.1016/j.yexcr.2004.02.018.
98. Shelton M, Metz J, Liu J, Carpenedo RL, et al. Derivation and expansion of PAX7-positive muscle progenitors from human and mouse embryonic stem cells. Stem Cell Rep 2014; 3: 516-29. doi: 10.1016/j.stemcr.2014.07.001.
99. Albini S, Coutinho P, Malecova B, Giordani L, et al. Epigenetic reprogramming of human embryonic stem cells into skeletal muscle cells and generation of contractile myospheres. Cell Rep 2013; 3: 661-70. doi: 10.1016/j.celrep.2013.02.012.
100. Davis RL, Weintraub H, Lassar AB. Expression of a single transfected cDNA converts fibroblasts to myoblasts. Cell 1987; 51: 987-1000.
101. Schäfer BW, Blakely BT, Darlington GJ, Blau HM. Effect of cell history on response to helix-loop-helix family of myogenic regulators. Nature 1990; 344: 454-8. doi: 10.1038/344454a0.
102. Rodin S, Antonsson L, Niaudet C, Simonson OE, et al. Clonal culturing of human embryonic stem cells on laminin-521/Ecadherin matrix in defined and xeno-free environment. Nat Commun 2014; 5. doi: 10.1038/ncomms4195.
103. De Miguel-Beriain I. The ethics of stem cells revisited. Adv Drug Deliv Rev 2015; 82-83: 176-80. doi: 10.1016/j.addr.2014.11.011.
104. Yamanaka S. Induced pluripotent stem cells: past, present, and future. Cell Stem Cell 2012; 10: 678-84. doi: 10.1016/j.stem.2012.05.005.
105. Chen G, Gulbranson DR, Hou Z, Bolin JM, et al. Chemically defined conditions for human iPSC derivation and culture. Nat Methods 2011; 8: 424-9. doi: 10.1038/nmeth.1593.
106. Liu Z, Tang Y, Lü S, Zhou J, et al. The tumourigenicity of iPS cells and their differentiated derivates. J Cell Mol Med 2013; 17: 782-91. doi: 10.1111/jcmm.12062.
107. Hong SG, Winkler T, Wu C, Guo V, et al. Path to the clinic: assessment of iPSC-based cell therapies in vivo in a nonhuman primate model. Cell Rep 2014; 7: 1298-309. doi: 10.1016/j.celrep.2014.04.019.
108. Kuang S, Gillespie MA, Rudnicki MA. Niche regulation of muscle satellite cell self-renewal and differentiation. Cell Stem Cell 2008; 2: 22-31. doi: 10.1016/j.stem.2007.12.012.
109. Pannérec A, Marazzi G, Sassoon D. Stem cells in the hood: the skeletal muscle niche. Trends Mol Med 2012; 18: 599-606. doi: 10.1016/j.molmed.2012.07.004.
110. Wang YX, Rudnicki MA. Satellite cells, the engines of muscle repair. Nat Rev Mol Cell Biol 2012; 13: 127-33. doi: 10.1038/nrm3265.
111. Maffioletti SM, Noviello M, English K, et al. Stem cell transplantation for muscular dystrophy: the challenge of immune response. BioMed Res Int 2014; 2014: 964010. doi: 10.1155/2014/964010.
112. Sicari BM, Agrawal V, Siu BF, Medberry CJ, et al. A murine model of volumetric muscle loss and a regenerative medicine approach for tissue replacement. Tissue Eng Part A 2012; 18: 1941-8. doi: 10.1089/ten.TEA.2012.0475.
113. Criswell TL, Corona BT, Wang Z, et al. The role of endothelial cells in myofiber differentiation and the vascularization and innervation of bioengineered muscle tissue in vivo. Biomaterials 2013; 34: 140-9. doi: 10.1016/j.biomaterials.2012.09.045.
114. Fuoco C, Rizzi R, Biondo A, Longa E, et al. In vivo generation of a mature and functional artificial skeletal muscle. EMBO Mol Med 2015; 7: 411-22. doi: 10.15252/emmm.201404062.
115. Inoue H, Nagata N, Kurokawa H, Yamanaka S. iPS cells: a game changer for future medicine. EMBO J 2014; 33: 409-17. doi: 10.1002/embj.201387098.
116. Ye L, Muench MO, Fusaki N, Beyer AI, et al. Blood cell-derived induced pluripotent stem cells free of reprogramming factors generated by Sendai viral vectors. Stem Cells Transl Med 2013; 2: 558-66. doi: 10.5966/sctm.2013-0006.
117. Zhou T, Benda C, Dunzinger S, Huang Y, et al. Generation of human induced pluripotent stem cells from urine samples. Nat Protoc 2012; 7: 2080-9. doi: 10.1038/nprot.2012.115.
118. Vaskova EA, Stekleneva AE, Medvedev SP, Zakian SM. "Epigenetic memory" phenomenon in induced pluripotent stem cells. Acta Naturae 2013; 5: 15-21.
119. Shtrichman R, Germanguz I, Itskovitz-Eldor J. Induced pluripotent stem cells (iPSCs) derived from different cell sources and their potential for regenerative and personalized medicine. Curr Mol Med 2013; 13: 792-805.
120. Quattrocelli M, Palazzolo G, Floris G, et al. Intrinsic cell memory reinforces myogenic commitment of pericyte-derived iPSCs. J Pathol 2011; 223: 593-603. doi: 10.1002/path.2845.
121. Sanchez-Freire V, Lee AS, Hu S, Abilez OJ, et al. Effect of human donor cell source on differentiation and function of cardiac induced pluripotent stem cells. J Am Coll Cardiol 2014; 64: 436-48. doi: 10.1016/j.jacc.2014.04.056.
122. Biasco L, Baricordi C, Aiuti A. Retroviral integrations in gene therapy trials. Mol Ther 2012; 20: 709-16. doi: 10.1038/mt.2011.289.
123. Kaji K, Norrby K, Paca A, Mileikovsky M, et al. Virus-free induction of pluripotency and subsequent excision of reprogramming factors. Nature 2009; 458: 771-5. doi: 10.1038/nature07864.
124. Stadtfeld M, Nagaya M, Utikal J, Weir G, Hochedlinger K. Induced pluripotent stem cells generated without viral integration. Science 2008; 322: 945-9. doi: 10.1126/science.1162494.
125. Cyranoski D. Japanese woman is first recipient of next-generation stem cells. Nature 2014. doi: 10.1038/nature.2014.15915.
126. Kamao H, Mandai M, Okamoto S, Sakai N, et al. Characterization of human induced pluripotent stem cell-derived retinal pigment epithelium cell sheets aiming for clinical application. Stem Cell Rep 2014; 2: 205-18. doi: 10.1016/j.stemcr.2013.12.007.
127. Nakano-Okuno M, Borah BR, Nakano I. Ethics of iPSC-Based Clinical Research for Age-Related Macular Degeneration: Patient- Centered Risk-Benefit Analysis. Stem Cell Rev 2014; 10: 743-52. doi: 10.1007/s12015-014-9536-x.
128. Darabi R, Pan W, Bosnakovski D, et al. Perlingeiro RCR. Functional myogenic engraftment from mouse iPS cells. Stem Cell Rev 2011; 7: 948-57. doi: 10.1007/s12015-011-9258-2.
129. Belay E, Mátrai J, Acosta-Sanchez A, Ma L, Quattrocelli M, Mátés L, et al. Novel hyperactive transposons for genetic modification of induced pluripotent and adult stem cells: a nonviral paradigm for coaxed differentiation. Stem Cells 2010; 28: 1760-71. doi: 10.1002/stem.501.
130. Filareto A, Parker S, Darabi R, et al. An ex vivo gene therapy approach to treat muscular dystrophy using inducible pluripotent stem cells. Nat Commun 2013; 4: 1549. doi: 10.1038/ncomms2550.
131. Maffioletti SM, Gerli MFM, Ragazzi M, et al. Efficient derivation and inducible differentiation of expandable skeletal myogenic cells from human ES and patient-specific iPS cells. Nat Protoc 2015; 10: 941-58. doi: 10.1038/nprot.2015.057.
132. Gerli MFM, Maffioletti SM, Millet Q, Tedesco FS. Transplantation of induced pluripotent stem cell-derived mesoangioblast-like myogenic progenitors in mouse models of muscle regeneration. J Vis Exp 2014: e50532. doi: 10.3791/50532.
133. Goudenege S, Lebel C, Huot NB, et al. Myoblasts derived from normal hESCs and dystrophic hiPSCs efficiently fuse with existing muscle fibers following transplantation. Mol Ther 2012; 20: 2153- 67. doi: 10.1038/mt.2012.188.
134. Tanaka A, Woltjen K, Miyake K, et al. Efficient and reproducible myogenic differentiation from human iPS cells: prospects for modeling Miyoshi Myopathy in vitro. PloS One 2013; 8: e61540. doi: 10.1371/journal.pone.0061540.
135. Yasuno T, Osafune K, Sakurai H, et al. Functional analysis of iPSC-derived myocytes from a patient with carnitine palmitoyltransferase II deficiency. Biochem Biophys Res Commun 2014; 448: 175-81. doi: 10.1016/j.bbrc.2014.04.084.
136. Abujarour R, Bennett M, Valamehr B, et al. Myogenic differentiation of muscular dystrophy-specific induced pluripotent stem cells for use in drug discovery. Stem Cells Transl Med 2014; 3: 149-60. doi: 10.5966/sctm.2013-0095.
137. Mizuno Y, Chang H, Umeda K, et al. Generation of skeletal muscle stem/progenitor cells from murine induced pluripotent stem cells. FASEB J 2010; 24: 2245-53. doi: 10.1096/fj.09-137174.
138. Awaya T, Kato T, Mizuno Y, et al. Selective Development of Myogenic Mesenchymal Cells from Human Embryonic and Induced Pluripotent Stem Cells. PLoS ONE 2012; 7: e51638. doi: 10.1371/journal.pone.0051638.
139. Borchin B, Chen J, Barberi T. Derivation and FACS-mediated purification of PAX3+/PAX7+ skeletal muscle precursors from human pluripotent stem cells. Stem Cell Rep 2013; 1: 620-31. doi: 10.1016/j.stemcr.2013.10.007.
140. Xu C, Tabebordbar M, Iovino S, et al. A Zebrafish Embryo Culture System Defines Factors that Promote Vertebrate Myogenesis across Species. Cell 2013; 155: 909-21. doi: 10.1016/j.cell.2013.10.023.
141. Patterson M, Chan DN, Ha I, Case D, et al. Defining the nature of human pluripotent stem cell progeny. Cell Res 2012; 22: 178-93. doi: 10.1038/cr.2011.133.
142. Chin MH, Mason MJ, Xie W, et al. Induced pluripotent stem cells and embryonic stem cells are distinguished by gene expression signatures. Cell Stem Cell 2009; 5: 111-23. doi: 10.1016/j.stem.2009.06.008.
143. Drukker M, Katz G, Urbach A, et al. Characterization of the expression of MHC proteins in human embryonic stem cells. Proc Natl Acad Sci U S A 2002; 99: 9864-9. doi: 10.1073/pnas.142298299.
144. Swijnenburg R-J, Tanaka M, Vogel H, et al. Embryonic stem cell immunogenicity increases upon differentiation after transplantation into ischemic myocardium. Circulation 2005; 112: I166-72. doi: 10.1161/CIRCULATIONAHA.104.525824.
145. Tabayoyong WB, Zavazava N. Meet the inlaws: embryonic stem cell derivatives meet the immune system. Cell Res 2009; 19: 397- 8. doi: 10.1038/cr.2009.38.
146. Zhao T, Zhang Z-N, Rong Z, Xu Y. Immunogenicity of induced pluripotent stem cells. Nature 2011; 474: 212-5. doi: 10.1038/nature10135.
147. Li O, English K, Tonlorenzi R, et al. Human iPSC-derived mesoangioblasts, like their tissue-derived counterparts, suppress T cell proliferation through IDO- and PGE-2-dependent pathways. F1000Research 2013; 2: 24. doi: 10.12688/f1000research.2-24.v1.
148. English K, Tonlorenzi R, Cossu G, Wood KJ. Mesoangioblasts suppress T cell proliferation through IDO and PGE-2-dependent pathways. Stem Cells Dev 2013; 22: 512-23. doi: 10.1089/scd.2012.0386.
149. Taylor CJ, Peacock S, Chaudhry AN, et al. Generating an iPSC bank for HLA-matched tissue transplantation based on known donor and recipient HLA types. Cell Stem Cell 2012; 11: 147-52. doi: 10.1016/j.stem.2012.07.014.
150. Roncarolo M-G, Battaglia M. Regulatory T-cell immunotherapy for tolerance to self antigens and alloantigens in humans. Nat Rev Immunol 2007; 7: 585-98. doi: 10.1038/nri2138.
151. Burzyn D, Kuswanto W, Kolodin D, et al. A special population of regulatory T cells potentiates muscle repair. Cell 2013; 155: 1282- 95. doi: 10.1016/j.cell.2013.10.054.
152. Lui KO, Boyd AS, Cobbold SP, et al. A role for regulatory T cells in acceptance of ESC-derived tissues transplanted across an major histocompatibility complex barrier. Stem Cells 2010; 28: 1905-14. doi: 10.1002/stem.506.
153. Kazuki Y, Hiratsuka M, Takiguchi M, et al. Complete genetic correction of ips cells from Duchenne muscular dystrophy. Mol Ther 2010; 18: 386-93. doi: 10.1038/mt.2009.274.
154. Tinsley J, Deconinck N, Fisher R, et al. Expression of full-length utrophin prevents muscular dystrophy in mdx mice. Nat Med 1998; 4: 1441-4. doi: 10.1038/4033.
155. Ma N, Liao B, Zhang H, Wang L, et al. Transcription activator-like effector nuclease (TALEN)-mediated gene correction in integration- free β-thalassemia induced pluripotent stem cells. J Biol Chem 2013; 288: 34671-9. doi: 10.1074/jbc.M113.496174.
156. Choi SM, Kim Y, Shim JS, Park JT, et al. Efficient drug screening and gene correction for treating liver disease using patient-specific stem cells. Hepatology 2013; 57: 2458-68. doi: 10.1002/hep.26237.
157. Osborn MJ, Starker CG, McElroy AN, Webber BR, Riddle MJ, Xia L, et al. TALEN-based gene correction for epidermolysis bullosa. Mol Ther 2013; 21: 1151-9. doi: 10.1038/mt.2013.56.
158. Xia G, Gao Y, Jin S, Subramony S, et al. Genome Modification Leads to Phenotype Reversal in Human Myotonic Dystrophy type 1 iPS-cell Derived Neural Stem Cells. Stem Cells 2015. doi: 10.1002/stem.1970.
159. Ousterout DG, Perez-Pinera P, Thakore PI, et al. Reading frame correction by targeted genome editing restores dystrophin expression in cells from Duchenne muscular dystrophy patients. Mol Ther 2013; 21: 1718-26. doi: 10.1038/mt.2013.111.
160. Ousterout DG, Kabadi AM, Thakore PI, et al. Correction of Dystrophin Expression in Cells from Duchenne Muscular Dystrophy Patients through Genomic Excision of Exon 51 by Zinc Finger Nucleases. Mol Ther 2014. doi: 10.1038/mt.2014.234.
161. Ousterout DG, Kabadi AM, Thakore PI, et al. Multiplex CRISPR/Cas9-based genome editing for correction of dystrophin mutations that cause Duchenne muscular dystrophy. Nat Commun 2015; 6: 6244. doi: 10.1038/ncomms7244.
162. Li HL, Fujimoto N, Sasakawa N, et al. Precise Correction of the Dystrophin Gene in Duchenne Muscular Dystrophy Patient Induced Pluripotent Stem Cells by TALEN and CRISPR-Cas9. Stem Cell Rep 2014. doi: 10.1016/j.stemcr.2014.10.013.
163. Aiuti A, Biasco L, Scaramuzza S, et al. Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science 2013; 341: 1233151. doi: 10.1126/science.1233151.
164. Biffi A, Montini E, Lorioli L, et al. Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science 2013; 341: 1233158. doi: 10.1126/science.1233158.